Latest news

• UCB/Amgen’s Evenity finally cleared for osteoporosis in Europe

  UCB and Amgen have finally claimed European approval for their osteoporosis drug Evenity, which becomes the first new drug for the disease in the EU since 2010. ... Anti-sclerostin antibody Evenity (romosozumab) – which works by increasing bine

• CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

  Initially received a negative opinion of the drug. The EMA’s main advisory committee has changed its position on UCB and Amgen’s application for their severe osteoporosis drug Evenity, recommending ... Now, it has backed Evenity – an

• CHMP backs Bayer’s tumour-agnostic drug Vitrakvi

  The CHMP also said it has agreed to re-examine Amgen’s osteoporosis drug Evenity (romosozumab) after issuing a negative opinion at its June meeting, and is also taking a fresh

• Tecentriq’s triple negative breast cancer use among key CHMP nods

  On Friday the CHMP’s most notable ruling was a negative opinion for UCB and Amgen’s severe osteoporosis drug Evenity.

• CHMP blocks UCB/Amgen’s Evenity approval for osteoporosis

  We are disappointed by the Committee's opinion and continue to believe that Evenity has a positive benefit:risk profile.”. ... Evenity is an anti-sclerostin antibody which works by blocking a pathway that inhibits bone growth, resulting in increased